{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06004245",
            "orgStudyIdInfo": {
                "id": "BP44474"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-503170-20-00",
                    "type": "REGISTRY",
                    "domain": "EU Trial Number"
                }
            ],
            "organization": {
                "fullName": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors",
            "officialTitle": "A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-evaluate-the-safety-pharmacokinetics-and-anti-tumor-activity-of-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-22",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-16",
            "studyFirstSubmitQcDate": "2023-08-16",
            "studyFirstPostDateStruct": {
                "date": "2023-08-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RO7589831 monotherapy in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. RO7589831 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, RO7589831 may be able to block the growth of these types of cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumors"
            ],
            "keywords": [
                "Deficient mismatch repair",
                "dMMR",
                "Microsatellite instability",
                "MSI"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "This is an open label study. Participants will be assigned to dose cohorts in the order in which they are enrolled. However, if two or more cohorts in the same part of the study are open for enrollment at the same time, participants will be randomized into these cohorts.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 220,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part I: RO7589831 Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: RO7589831"
                    ]
                },
                {
                    "label": "Part II: RO7589831 Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: RO7589831"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RO7589831",
                    "description": "RO7589831 will be administered orally and once daily (QD) in 3-week cycles.",
                    "armGroupLabels": [
                        "Part I: RO7589831 Dose Escalation",
                        "Part II: RO7589831 Dose Expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Adverse Events, with Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)",
                    "timeFrame": "From first dose of study drug until 30 days after last dose of study drug (up to approximately 15 months)"
                },
                {
                    "measure": "Incidence of Dose-Limiting Toxicities",
                    "timeFrame": "Cycle 1 (1 cycle is 3 weeks)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum Plasma Concentration Observed (Cmax) of RO7589831",
                    "timeFrame": "At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)"
                },
                {
                    "measure": "Time of Maximum Plasma Concentration Observed (Tmax) of RO7589831",
                    "timeFrame": "At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)"
                },
                {
                    "measure": "Area Under the Plasma Concentration-Time Curve (AUC) of RO7589831",
                    "timeFrame": "At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)"
                },
                {
                    "measure": "Apparent Oral Clearance (CL/F) of RO7589831",
                    "timeFrame": "At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)"
                },
                {
                    "measure": "Volume of Distribution (V/F) of RO7589831",
                    "timeFrame": "At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)"
                },
                {
                    "measure": "Terminal Half-Life (T1/2) of RO7589831",
                    "timeFrame": "At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)"
                },
                {
                    "measure": "Objective Response Rate",
                    "timeFrame": "From start of study treatment until end of follow-up (up to approximately 36 months)"
                },
                {
                    "measure": "Disease Control Rate",
                    "timeFrame": "From start of study treatment until end of follow-up (up to approximately 36 months)"
                },
                {
                    "measure": "Duration of Response",
                    "timeFrame": "From the time of first occurrence of a documented response until the time of documented disease progression or death from any cause, whichever occurs first (up to approximately 36 months)"
                },
                {
                    "measure": "Progression-Free Survival, as Assessed by the Investigator",
                    "timeFrame": "From start of study treatment to the first occurrence of documented disease progression or death from any cause, whichever occurs first (up to approximately 36 months)"
                },
                {
                    "measure": "Overall Survival",
                    "timeFrame": "From start of study treatment to the time of death from any cause (up to approximately 36 months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Have a locally confirmed microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor\n* Have received and then progressed following or are intolerant to at least 1 standard treatment regimen in the advanced setting\n* Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\n* Life expectancy of at least (\u2265)12 weeks\n* Availability of formaldehyde-fixed paraffin-embedded (FFPE) archival tumor tissue for submission to Sponsor/central laboratory for retrospective central testing; for participants without archival tissue, a biopsy from either primary or metastatic tumor lesion, deemed medically feasible, must be taken\n* Adequate hematologic, end-organ, and cardiovascular function, as defined in the protocol\n\nExclusion Criteria:\n\n* Inability or unwillingness to swallow pills\n* Malabsorption syndrome or other condition that would interfere with enteral absorption\n* Known hypersensitivity or intolerance to ingredients from the study drug formulation including patients with rare genetic disorders such as galactosaemia, glucose-galactose intolerance or congenital lactase deficiency\n* Known uncontrolled central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) and/or carcinomatous meningitis\n* Known active or uncontrolled bacterial, viral, fungal, mycobacterial (including but not limited to tuberculosis and atypical mycobacterial disease), parasitic, or other infection (excluding fungal infections of nail beds), or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 2 weeks prior to the start of drug administration (related to the completion of the course of antibiotics, except if for tumor fever) or 6 months for any intracranial abscess\n* Has a positive test at screening for hepatitis B virus, hepatitis C virus, or for human immodeficiency virus (HIV), per local diagnostic standard and in accordance with local laws and regulations\n* Uncontrolled diabetes or symptomatic hyperglycemia (i.e., well controlled defined as a screening hemoglobin A1c \\<8% and no urinary ketoacidosis)\n* Alcohol or drug dependence or abuse\n* Patients with known Werner (WRN) syndrome\n* Prior treatment with any WRN helicase inhibitor\n* Pregnancy, breastfeeding, or intention of becoming pregnant during the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: BP44474 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S. Only)",
                    "email": "global-roche-genentech-trials@gene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Hoffmann-La Roche",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "City of Hope at Irvine Lennar",
                    "status": "RECRUITING",
                    "city": "Irvine",
                    "state": "California",
                    "zip": "92618",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.66946,
                        "lon": -117.82311
                    }
                },
                {
                    "facility": "Duke University; Office of Research Contracts",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27705",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "SCRI Oncology Partners",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "UZ Leuven Gasthuisberg",
                    "status": "RECRUITING",
                    "city": "Leuven",
                    "zip": "3000",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 50.87959,
                        "lon": 4.70093
                    }
                },
                {
                    "facility": "BCCA-Vancouver Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "state": "British Columbia",
                    "zip": "V5Z 4E6",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Rigshospitalet; Onkologisk Klinik",
                    "status": "RECRUITING",
                    "city": "K\u00f8benhavn \u00d8",
                    "zip": "2100",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 55.67594,
                        "lon": 12.56553
                    }
                },
                {
                    "facility": "CLCC Leon Berard Lyon",
                    "status": "RECRUITING",
                    "city": "Lyon",
                    "zip": "69008",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.74848,
                        "lon": 4.84669
                    }
                },
                {
                    "facility": "Gustave Roussy",
                    "status": "RECRUITING",
                    "city": "Villejuif",
                    "zip": "94805",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Clinica Universitaria de Navarra; Servicio de Oncologia",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "state": "Navarra",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Vall d?Hebron Institute of Oncology (VHIO), Barcelona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Clinica Universidad de Navarra Madrid; Servicio de Oncolog\u00eda",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28027",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "START Madrid. Centro Integral Oncologico Clara Campal; CIOCC",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia",
                    "status": "RECRUITING",
                    "city": "Valencia",
                    "zip": "46010",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 39.46975,
                        "lon": -0.37739
                    }
                },
                {
                    "facility": "Royal Marsden Hospital - Fulham",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "SW3 6JJ",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "W1G 6AD",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "The Christie",
                    "status": "RECRUITING",
                    "city": "Manchester",
                    "zip": "M20 4BX",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000053842",
                    "term": "Microsatellite Instability"
                }
            ],
            "ancestors": [
                {
                    "id": "D000042822",
                    "term": "Genomic Instability"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M27510",
                    "name": "Microsatellite Instability",
                    "asFound": "Microsatellite Instability",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25088",
                    "name": "Genomic Instability",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}